Article

Daily Medication Pearl: Meropenem IV

Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure infections.

Medication Pearl of the Day: Meropenem IV

Indication: Meropenem IV is an antibacterial medication indicated for the treatment of complicated stomach and skin structure bacterial infections in adult and pediatric patients 3 months of age and older; complicated intra-abdominal infections in adult and pediatric patients; and bacterial meningitis in patients 3 months of age and older.

Insight:

  • Dosing: 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa, a dose of 1 gram every 8 hours is recommended.
  • Dosage forms: 500 mg meropenem for injection vial (3) 1-gram meropenem for injection vial.
  • Adverse events: Most common adverse reactions (2% or less) are headache, nausea, constipation, diarrhea, anemia, vomiting, and rash.
  • Mechanism of action: Meropenem penetrates the cell wall of most gram-positive and gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Meropenem binds to PBPs 2, 3, and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2, and 4 of Staphylococcus aureus. Bactericidal concentrations (defined as a 3 log10 reduction in cell counts within 12 hours to 24 hours) are typically 1-2 times the bacteriostatic concentrations of meropenem, with the exception of Listeria monocytogenes, against which lethal activity is not observed.

Source: Label: MERREM IV (meropenem for injection), (fda.gov)

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com